Joe Todisco , Chief Executive Officer ofCorMedix , officially joined the organization onTuesday May 10 th.Liz Hurlburt , EVP of Clinical Operations, has been promoted to an expanded role as EVP of Clinical & Medical Affairs, assuming oversight of Medical Affairs, Drug Safety and Pharmacovigilance, in addition to her existing Clinical Operations responsibilities.Donna Ucci has joined the Company as Senior Vice President and Head of Global Quality, reporting directly to the CEO. Donna joinsCorMedix after most recently serving as VP Global Quality Management at Amneal Pharmaceuticals, and with more than 20 years Quality leadership experience in previous roles at Impax, Allergan, and Pfizer.Frank Raffaele has joined the company as VP of Supply Chain, and brings more than 30 years of manufacturing and supply chain experience, most recently withQuotient Sciences andTeva Pharmaceuticals .- The Company and
Tom Nusbickel , EVP and Chief Commercial Officer, have mutually agreed to part ways. - The Company will begin the process of winding down its European operations and will discontinue the distribution of Neutrolin, which is CE marked as a medical device in
Europe . The Company intends to focus near-term efforts on securing NDA approval and commercialization of DefenCath in the US market.
“I am excited to begin my tenure this week at CorMedix,” said
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects, future financial position, financing plans, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including: the results of our discussions with the FDA regarding the DefenCath development path for marketing authorization; the resources needed to secure approval of the new drug application for DefenCath from the FDA; our ability to address the deficiencies identified at our CMO in connection with the manufacture of DefenCath; the risks and uncertainties associated with CorMedix’s ability to manage its limited cash resources and the impact on current, planned or future research, including the continued development of DefenCath/Neutrolin and research for additional uses for taurolidine; obtaining additional financing to support CorMedix’s research and development and clinical activities and operations; preclinical results are not indicative of success in clinical trials and might not be replicated in any subsequent studies or trials; and the ability to retain and hire necessary personnel to staff our operations appropriately. We continue to assess to what extent the uncertainty surrounding the Coronavirus pandemic may impact our business and operations. These and other risks are described in greater detail in CorMedix’s filings with the
Investor Contact:
Managing Director
daniel@lifesciadvisors.com
(617) 430-7576
Source:
2022 GlobeNewswire, Inc., source